Insights from Uncommon Thinkers: How these innovators found novel approaches in their fields
This week on the GeekWire Podcast, we sit down with some of the Seattle region’s “Uncommon Thinkers” — inventors, scientists, technologists and entrepreneurs transforming industries and driving positive change in the world. We recorded the episode on location, backstage at the GeekWire Gala, where we recognized five Uncommon Thinkers through this annual awards program, presented in partnership with Greater Seattle Partners. Speaking on the episode are: Uri Shumlak, co-founder and chief scientist at Zap Energy, a physicist leading a team in pursuit of fusion energy, taking a different approach from others in the field. Read the profile. Ingrid Swanson Pultz…
Fundamentals for Startups: The PvP Biologics story: A molecule from concept to commercial use
(https://comotion.uw.edu) Dr. Ingrid Swanson Pultz described the founding and spinning out of her company, PvP Biologics, from the UW's Institute for Protein Design and its eventual acquisition by Takeda Pharmaceuticals. She discussed the key points that led to the success of PvP and described the challenges encountered throughout their journey. Dr. Ingrid Swanson Pultz is Chief Technology Officer at Mopac Biologics and a Translational Advisor at the Institute for Protein Design (IPD). She was Chief Scientific Officer of PvP Biologics, an IPD spin out company acquired by Takeda Pharmaceuticals in 2020, and served as the CEO for PvP in its…
Takeda buys Seattle startup PvP Biologics for up to $330M, will advance TAK-062 into Phase 2
Japanese pharmaceutical Takeda acquired Seattle biotech PvP Biologics for up to $330 million in late February, taking over its TAK-062 (Kuma062) program and all clinical and manufacturing activities while laying off PvP staff. Takeda plans to run phase 2 trials of the enzyme-based celiac disease treatment that PvP developed after earlier funding of $35 million supported phase 1 work.
Organizations
-
Mopac Chief Technology Officer · current
-
Mopac Biologics CTO and Translational Advisor · current
-
University of Washington Protein Design Researcher · current
Questions about Ingrid Swanson Pultz
Who is Ingrid Swanson Pultz?
Ingrid Swanson Pultz is chief technology officer at Mopac and CTO and translational advisor at Mopac Biologics.
What is Ingrid Swanson Pultz known for?
Ingrid Swanson Pultz is known for academic protein design work as a protein design researcher at University of Washington.
What has Ingrid Swanson Pultz been in the news for?
GeekWire reported in April 2020 that Takeda would advance PvP Biologics’ TAK-062 into Phase 2.
Which organizations is Ingrid Swanson Pultz associated with?
Ingrid Swanson Pultz is currently chief technology officer at Mopac, CTO and translational advisor at Mopac Biologics, and a protein design researcher at University of Washington.
Where is Ingrid Swanson Pultz based?
Ingrid Swanson Pultz is based in the Seattle area.